Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

John Mascarenhas(Tisch Hospital), Jean‐Jacques Kiladjian(Délégation Paris 5), Ronald Hoffman(Icahn School of Medicine at Mount Sinai), Rami S. Komrokji(Moffitt Cancer Center), Andreas Reiter(Heidelberg University), Faye Feller(Geron (United States)), Dietger Niederwieser(Leipzig University of Applied Sciences), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Maria R. Baer(University of Maryland, Baltimore), Jacqueline Bussolari(Johnson & Johnson (United States)), Olatoyosi Odenike(University of Chicago), Fei Huang(Children's Hospital of Zhejiang University), Laurie Sherman(Geron (United States)), Bart L. Scott(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ying Wan(Geron (United States)), Souria Dougherty(Geron (United States)), Libo Sun(Children's Hospital of Fudan University), Eugene Zhu(Janssen (United States)), Aleksandra Rizo(Geron (United States)), Francesca Palandri(Istituto Oncologico Romagnolo), Bruno Martino(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Esther Rose(The University of Texas MD Anderson Cancer Center)
Journal of Clinical Oncology
June 17, 2021
Cited by 107


Related Papers